Australia markets closed

Corcept Therapeutics Incorporated (CORT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
23.01-0.51 (-2.17%)
At close: 04:00PM EST
23.01 0.00 (0.00%)
After hours: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close23.52
Open23.48
Bid0.00 x 800
Ask0.00 x 1000
Day's range22.64 - 23.56
52-week range16.47 - 30.14
Volume928,732
Avg. volume594,963
Market cap2.477B
Beta (5Y monthly)0.53
PE ratio (TTM)22.56
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Corcept Therapeutics Provides Miricorilant Clinical Development Update

    MENLO PARK, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today announced an update to its programs evaluating the proprietary selective cortisol modulator miricorilant in patients with antipsychotic-induced weight gain (AIWG) and non-alcoholic

  • GlobeNewswire

    Corcept Therapeutics Settles Patent Litigation with Hikma Pharmaceuticals

    MENLO PARK, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today announced that it has entered into an agreement with Hikma Pharmaceuticals USA Inc. ("Hikma") resolving patent litigation related to Korlym®, Corcept’s medication for the treatment

  • GlobeNewswire

    Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

    MENLO PARK, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended September 30, 2022. Financial Results Revenue of $101.7 million, compared to $96.1 million in third quarter 2021Tightened 2022 revenue gui